证券代码：300289 证券简称：利德曼 公告编号：2023-026 北京利德曼生化股份有限公司 关于举行2022年度网上业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 北京利德曼生化股份有限公司（以下简称"公司"）已于 2023 年 3 月 25 日在巨潮资讯网（http://www.cninfo.com.cn）上披露了《2022 年年度报告》及《2022 年年度报告摘要》。 为便于广大投资者更深入全面地了解公司经营情况，公司定于 2023 年 4 月 11 日（星期二）下午 15:00 至 17:00 时举行 2022 年度业 绩说明会。本次年度业绩说明会将采取网络远程方式举行，投资者可 通过以下方式参与本次互动交流： 参与方式一：在微信中搜索"利德曼投资者关系小程序"； 参与方式二：微信扫描以下二维码： 投资者依据提示，授权登入"利德曼投资者关系"小程序，即可 参与交流。 为提升交流效率和针对性，以及做好中小投资者保护工作，广泛 听取投资者的意见和建议，增进投资者对公司的了解和认同，提升公 司治理水平和企业整体价值，现提前向投资者征集相 ...

Financial Performance - The company achieved operating revenue of 705.9768 million yuan, an increase of 25.16% compared to the same period last year[4]. - The net profit attributable to shareholders was -56.2718 million yuan, a decrease of 351.00% year-on-year, primarily due to goodwill impairment of 30.5286 million yuan and credit impairment of 27.5273 million yuan[4]. - The company's operating revenue for 2022 was ¥705,976,839.21, representing a 25.16% increase compared to ¥564,057,983.88 in 2021[27]. - The net profit attributable to shareholders for 2022 was -¥56,271,757.90, a decrease of 351.00% from a profit of ¥22,419,197.58 in 2021[27]. - The net cash flow from operating activities was ¥108,933,825.70, a decline of 8.50% from ¥119,058,284.44 in 2021[27]. - The total assets at the end of 2022 were ¥1,997,134,641.92, a decrease of 14.96% from ¥2,348,410,268.66 at the end of 2021[27]. - The net assets attributable to shareholders at the end of 2022 were ¥1,727,304,693.21, down 5.87% from ¥1,835,030,234.33 in 2021[27]. - The basic earnings per share for 2022 was -¥0.10, compared to ¥0.05 in 2021, reflecting a 300.00% decrease[27]. - The weighted average return on net assets was -3.13% in 2022, a decline of 4.66% from 1.53% in 2021[27]. - The company reported uncertainty regarding its ability to continue as a going concern, as both net profits before and after deducting non-recurring gains and losses have been negative for the last three accounting years[27]. Revenue Sources - Revenue from epidemic prevention testing business was 254.20 million yuan, with future revenue expected to focus on biochemical and immunodiagnostic products[4]. - The in vitro diagnostic reagent business generated revenue of 619.81 million yuan, up 28.43% year-on-year, accounting for 87.79% of total revenue[57]. - Revenue from the biopharmaceutical sector was ¥675,935,938.66, accounting for 95.74% of total revenue, with a growth of 24.96% year-on-year[84]. - The East China region contributed ¥467,722,330.17, which is 66.25% of total revenue, showing a significant growth of 62.27% year-on-year[84]. - The distribution sales model accounted for ¥566,472,687.71, or 80.24% of total revenue, with a year-on-year increase of 30.35%[84]. Research and Development - The company emphasizes continuous investment in R&D, upgrading existing products, and expanding product lines to meet end-user testing needs[57]. - The company has established multiple product development and technology innovation platforms, including biochemical and immunodiagnostic reagent development platforms[61]. - The company is actively investing in research and development for high-tech immunodiagnostic products, which are characterized by high technological content and long development cycles[41]. - The company has a R&D team of 73 people, with 29 holding master's degrees or higher, contributing to its core competitiveness in technology development[63]. - The company reported a research and development expenditure of ¥34,957,360.92 in 2022, which represents 4.95% of its operating revenue[98]. - The company has registered and launched multiple new test kits, including those for rT3, DHEAS, and S100, enhancing its testing menu in various categories[97]. - The company aims to enhance its biochemical detection capabilities and expand its testing menu for conditions such as hypertension and anemia[96]. Market and Competition - The company operates in the in vitro diagnostics (IVD) industry, which is projected to reach USD 59.45 billion in sales by 2024, with a compound annual growth rate (CAGR) of 6.1% from 2017 to 2024[38]. - The domestic IVD market size was estimated at approximately CNY 146 billion in 2022, with a six-year CAGR of about 21%, highlighting rapid growth in the sector[39]. - Increased market competition in the in vitro diagnostics industry may affect the company's operational performance if it cannot maintain its core competitiveness[7]. - The domestic biochemical diagnostic field has a current domestic substitution rate of approximately 70%, indicating significant market potential for domestic products[62]. - The company is focusing on collaboration with universities and research institutions to drive innovation and product development[63]. Governance and Compliance - The company has established a comprehensive corporate governance structure in compliance with relevant laws and regulations, ensuring the protection of shareholder interests and sustainable development[146]. - The company maintains transparency in information disclosure, ensuring all shareholders have equal access to information[153]. - The company has established a performance evaluation and incentive mechanism for senior management, linking compensation to performance[151]. - The company has not experienced any significant deviations from the governance regulations set by the China Securities Regulatory Commission[154]. - The company is committed to ensuring the accuracy of its financial reporting and compliance with regulations[122]. Strategic Initiatives - The company plans to improve profitability through product system layout, accelerate new product launches, and optimize supply chain management[4]. - The company is focusing on expanding its product line in molecular diagnostics and point-of-care testing (POCT) to meet diverse market demands[40]. - The company is actively adjusting its marketing strategies through various channels to enhance brand recognition and academic influence[58]. - The company plans to continue its strategic initiatives in market expansion and product development[117]. - The company aims to improve its market position through continuous innovation and product development[100]. Risks and Challenges - The company faces risks from industry policy changes, including centralized procurement and price control measures that may impact profitability[5]. - The company is at risk of asset impairment due to potential uncollectible receivables from downstream customers affected by economic conditions[10]. - The company reported a significant increase in external purchase costs, which rose by 127.58% year-on-year to ¥268,966,074.25[88]. - The company is committed to enhancing its governance structure and internal control systems to reduce operational compliance risks and improve information disclosure quality[141].

Financial Performance - The company's revenue for Q3 2022 was ¥167,677,605.14, a decrease of 0.66% compared to the same period last year, while year-to-date revenue increased by 30.81% to ¥541,955,931.31[4] - Net profit attributable to shareholders for Q3 2022 was ¥10,533,956.80, down 32.01% year-on-year, with year-to-date net profit increasing by 18.62% to ¥34,469,678.83[4] - The net profit after deducting non-recurring gains and losses for Q3 2022 was ¥8,682,676.22, a decrease of 43.57% year-on-year, while year-to-date it increased by 10.97% to ¥29,757,670.58[4] - Total operating revenue for the third quarter reached ¥541,955,931.31, an increase of 30.8% compared to ¥414,305,890.57 in the same period last year[23] - Net profit for the period was ¥49,863,077.17, slightly down from ¥50,012,250.46 in the previous year, representing a decrease of 0.3%[24] - The net profit attributable to shareholders of the parent company was ¥34,469,678.83, an increase of 18.3% compared to ¥29,057,757.37 in the same period last year[24] Cash Flow - The company's cash flow from operating activities for the year-to-date period was ¥78,295,528.10, an increase of 58.81% compared to the previous year[4] - The cash inflow from operating activities for Q3 2022 was CNY 667,753,861.95, an increase of 26.9% compared to CNY 525,904,241.09 in Q3 2021[27] - The cash flow from operating activities netted CNY 78,295,528.10, which is a 58.8% increase compared to CNY 49,300,438.01 in Q3 2021[27] - The cash received from other operating activities was CNY 11,647,624.61, compared to CNY 9,669,930.04, marking a 20.5% increase[27] Operating Costs - Operating costs increased by 56.40% year-to-date, mainly due to the purchase of COVID-19 testing reagents[9] - Total operating costs amounted to ¥478,638,335.45, up 36.3% from ¥350,959,659.12 year-on-year[23] - The cash paid for purchasing goods and services was CNY 374,893,475.53, up from CNY 274,669,214.59, indicating a 36.4% increase in operational costs[27] Assets and Liabilities - The total assets at the end of Q3 2022 were ¥2,338,864,516.45, a decrease of 0.41% from the end of the previous year[4] - Total liabilities amounted to ¥322,499,967.10, a decrease from ¥370,301,842.38 at the end of the previous period[23] - The company has a total asset value of 2,338,864,516.45 CNY as of September 30, 2022, down from 2,348,410,268.66 CNY at the beginning of the year[20] Shareholder Information - The total number of common shareholders at the end of the reporting period is 24,378[13] - The largest shareholder, Guangzhou High-tech Zone Technology Holding Group Co., Ltd., holds 46.35% of shares, totaling 252,133,152 shares[13] Research and Development - Research and development expenses for the quarter were ¥28,351,916.96, up from ¥24,493,747.55 year-on-year, indicating a focus on innovation[23] - The company has added 8 new patent authorizations during the reporting period, including a method for detecting invasive fungal infections[17] Investment Activities - The net cash outflow from investing activities was CNY -327,437,026.83, compared to CNY -25,002,514.27 in the same period last year, indicating a significant increase in investment expenditures[27] - The company reported a significant increase in cash outflows for investment activities, totaling CNY 660,432,992.86, compared to CNY 59,171,716.40 in the previous year[27] Goodwill and Other Assets - The company has a total of 190,072,267.77 CNY in goodwill, unchanged from the beginning of the year[20] - The company has a total of 149,905,196.83 CNY in investment properties as of September 30, 2022[20]

Financial Performance - The company's operating revenue for the first half of 2022 was ¥374,278,326.17, representing a 52.45% increase compared to ¥245,516,200.97 in the same period last year[19]. - The net profit attributable to shareholders for the first half of 2022 was ¥23,935,722.03, a 76.46% increase from ¥13,564,130.88 in the previous year[19]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥21,074,994.36, up 84.39% from ¥11,429,604.00 in the same period last year[19]. - The net cash flow from operating activities was ¥65,270,176.97, an increase of 59.55% compared to ¥40,908,999.89 in the previous year[19]. - Basic earnings per share for the first half of 2022 were ¥0.0440, a 35.38% increase from ¥0.0325 in the same period last year[19]. - The company achieved operating revenue of 374.28 million yuan, a year-on-year increase of 52.45%[39]. - Net profit attributable to shareholders reached 23.94 million yuan, up 76.46% compared to the same period last year[39]. - The total profit for the first half of 2022 was CNY 44,981,200.48, up from CNY 30,848,667.26 in the previous year, marking a growth of approximately 45.6%[196]. Assets and Liabilities - Total assets at the end of the reporting period were ¥2,319,061,757.28, a decrease of 1.25% from ¥2,348,410,268.66 at the end of the previous year[19]. - The net assets attributable to shareholders at the end of the reporting period were ¥1,848,088,909.54, reflecting a 0.71% increase from ¥1,835,030,234.33 at the end of the previous year[19]. - Total liabilities decreased to CNY 316,628,682.32 from CNY 370,301,842.38, reflecting a reduction of approximately 14.5%[190]. - Cash and cash equivalents stood at CNY 595,970,466.48, down from CNY 652,630,393.05 at the beginning of the year[192]. Research and Development - The company invested 16.77 million yuan in R&D, reflecting a year-on-year increase of 9.75%[39]. - The company achieved a total R&D investment of 16.77 million yuan, representing a year-on-year increase of 9.75%, with R&D expenses accounting for 4.48% of operating revenue[55]. - The company is actively collaborating with universities and research institutions to enhance product development and innovation[38]. - The company’s R&D projects focus on three main areas: in vitro diagnostic reagents, diagnostic instruments, and biochemical raw materials[54]. Market and Sales - The company achieved revenue of ¥306,021,400 from the distribution model, accounting for 85.85% of total revenue, while direct sales generated ¥50,438,000, representing 14.15% of total revenue[36]. - The company has a strong market presence with a nationwide sales channel and technical service network covering various medical institutions[28]. - The domestic in vitro diagnostic market is expected to reach 129 billion yuan in 2022, with a compound annual growth rate of 20.39% from 2017 to 2020[47]. - The company’s sales model combines distribution and direct sales, with a focus on distribution in regions with strong distributor resources[36]. Product Development - The company has obtained 71 product registration certificates for its immunodiagnostic reagents, which include various disease detection menus[29]. - The company has launched 2 new monoclonal antibody products (PGI, PGII) and has 6 ongoing projects for recombinant antibodies[55]. - The company is developing a compact, fast, and cost-effective POCT detection platform, which is currently in the product development stage and will supplement the POCT instrument product line[57]. - The company is expanding its product offerings with new assay kits for various health conditions, including the Insulin-like Growth Factor I and Prostate-Specific Antigen kits, which are in the product development stage[56]. Risks and Challenges - The company faces risks from industry policy changes, including price pressures from centralized procurement and regulatory reforms[100]. - Increased market competition in the in vitro diagnostics sector may impact revenue and market share if the company fails to enhance product quality and coverage[101]. - The company faces risks of revenue and profit decline due to the impact of the pandemic and changes in domestic epidemic prevention policies[106]. - The company is actively managing accounts receivable risks due to potential payment delays from downstream customers[104]. Environmental and Social Responsibility - The company has invested over 800,000 RMB in new wastewater treatment facilities to reduce pollutant emissions[117]. - The company has implemented online monitoring systems for wastewater discharge, ensuring compliance with environmental standards[117]. - The company has established an energy-saving team, achieving over 15% reduction in power consumption through smart control systems and over 30% reduction in lighting energy by replacing incandescent bulbs with LED[119]. - The company plans to initiate targeted poverty alleviation efforts in the second half of 2022 to support sustainable development in impoverished areas[127]. Corporate Governance - The company has a governance structure with 7 board members, including 3 independent directors, ensuring clear responsibilities and checks and balances[120]. - The company has established a complete and independent organizational structure for corporate governance[131]. - The management team is composed of dedicated professionals, with all senior management receiving salaries exclusively from the company[133]. - The company has committed to avoiding any competition with its subsidiaries and will notify the listed company of any potential business opportunities that may lead to competition[130].

Financial Performance - The company's revenue for Q1 2022 was CNY 191,578,138.79, representing a 65.55% increase compared to CNY 115,723,080.99 in the same period last year[3] - Net profit attributable to shareholders for Q1 2022 was CNY 12,109,083.40, a 93.14% increase from CNY 6,269,691.46 year-on-year[3] - Basic and diluted earnings per share increased by 46.67% to CNY 0.022 from CNY 0.015 in the same period last year[3] - Net profit for Q1 2022 reached CNY 18,442,533.26, representing a 72.5% increase from CNY 10,683,942.73 in Q1 2021[27] - The total comprehensive income for the period was CNY 18,442,533.26, compared to CNY 10,683,942.73 in the previous period, representing an increase of approximately 72.5%[28] - The net profit attributable to the parent company was CNY 12,109,083.40, up from CNY 6,269,691.46, indicating a growth of about 93.5%[28] Cash Flow - The net cash flow from operating activities decreased by 71.75% to CNY 4,331,880.00, down from CNY 15,336,177.92 in the previous year[3] - Cash inflows from operating activities totaled CNY 248,793,538.36, compared to CNY 160,370,670.55 in the previous period, marking an increase of about 55%[30] - The net cash flow from operating activities was CNY 4,331,880.00, down from CNY 15,336,177.92, a decrease of approximately 71.7%[31] - Cash outflows from investment activities amounted to CNY 323,298,262.18, significantly higher than CNY 10,064,308.00 in the previous period[31] - The net cash flow from investment activities was negative at CNY -322,868,262.18, compared to CNY -9,887,308.00 previously[31] - The net cash flow from financing activities was CNY -4,452,419.68, a decrease from CNY -38,153,616.67 in the previous period, indicating an improvement[31] - The ending cash and cash equivalents balance was CNY 605,551,274.77, compared to CNY 319,826,863.94 at the end of the previous period, an increase of approximately 89.5%[32] Assets and Liabilities - Total assets at the end of the reporting period were CNY 2,338,149,870.85, a slight decrease of 0.44% from CNY 2,348,410,268.66 at the end of the previous year[3] - Total liabilities decreased to CNY 342,328,818.59 from CNY 370,301,842.38, indicating a reduction of approximately 7.6%[24] - The company's total equity attributable to shareholders increased by 0.66% to CNY 1,847,139,317.73 from CNY 1,835,030,234.33 at the end of the previous year[3] - The equity attributable to shareholders of the parent company increased to CNY 1,847,139,317.73 from CNY 1,835,030,234.33, reflecting a growth of 0.7%[25] Operating Costs and Expenses - The company reported a significant increase in operating costs, which rose by 123.72% to CNY 118,966,900.00 due to higher sales volumes[10] - Total operating costs for Q1 2022 were CNY 167,908,589.76, up 64.5% from CNY 101,996,186.58 year-on-year[26] - Research and development expenses for Q1 2022 were CNY 9,130,522.32, slightly down from CNY 9,259,306.78 in the previous year[26] - The company’s tax expenses rose by 68.20% to CNY 446,630.00, reflecting increased profits from its subsidiary[11] Business Development - The in vitro diagnostic reagent business generated revenue of 165.39 million RMB, accounting for 86.33% of total revenue, with a growth of 65.55% year-on-year[18] - The company obtained 8 new medical device registration certificates for in vitro diagnostic reagents during the reporting period[19] - The company launched 4 new biochemical diagnostic reagents and 5 new chemiluminescent diagnostic reagents[19] - The company received 1 invention patent and 2 utility model patents during the reporting period[20] - Other business income, mainly from property leasing, increased by 50.25% year-on-year to 7.56 million RMB, making up 3.95% of total revenue[18] Miscellaneous - The report for the first quarter was not audited[32]

Financial Performance - The company's operating revenue for 2021 was ¥564,057,983.88, representing a 19.63% increase compared to ¥471,510,962.68 in 2020[23]. - The net profit attributable to shareholders for 2021 was ¥22,419,197.58, a significant turnaround from a loss of ¥50,983,731.69 in 2020, marking a 143.97% improvement[23]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥12,765,279.02, up 122.95% from a loss of ¥55,617,631.18 in the previous year[23]. - The company's total assets increased by 44.20% to ¥2,348,410,268.66 at the end of 2021, compared to ¥1,628,633,453.83 at the end of 2020[23]. - The net assets attributable to shareholders rose by 45.45% to ¥1,835,030,234.33 at the end of 2021, up from ¥1,261,642,033.09 in 2020[23]. - The basic earnings per share for 2021 was ¥0.05, a recovery from a loss of ¥0.12 in 2020, reflecting a 141.67% increase[23]. - The weighted average return on net assets was 1.54% in 2021, compared to -3.95% in 2020, indicating improved profitability[23]. - The net cash flow from operating activities was ¥119,058,284.44, a decrease of 12.17% from ¥135,559,303.27 in 2020[23]. - The company achieved operating revenue of 564.058 million yuan, representing a year-on-year growth of 19.63%[47]. - The net profit attributable to shareholders of the listed company was 22.4192 million yuan[47]. Market and Industry Position - The company is positioned in the in vitro diagnostic industry, which is expected to reach a sales volume of 59.45 billion USD by 2024, with a CAGR of 6.1% from 2017 to 2024[32]. - The in vitro diagnostic industry in China is projected to grow significantly, driven by factors such as an aging population and increased health awareness, with the market size reaching approximately 90 billion yuan in 2020[49][50]. - The domestic market for immunodiagnostics is expected to see substantial growth, with a current domestic replacement rate of only 20% in the chemiluminescence sector, indicating significant market potential[50]. - The company is focusing on expanding its market presence and enhancing its product offerings through new technology development[152]. - The company plans to enhance its market presence and competitiveness in the in vitro diagnostic sector, narrowing the gap with foreign enterprises[117]. Research and Development - The company has a strong focus on R&D in the in vitro diagnostics (IVD) sector, which is expected to drive future growth[19]. - The company is actively investing in research and development for chemiluminescence immunodiagnostic products, which have a high technological content and low domestic replacement rate[36]. - The company aims to enhance its product line and maintain technological leadership by increasing R&D investment, particularly in biochemical reagents and chemiluminescence products[122]. - The company is developing a compact, fast, and cost-effective POCT detection platform to enhance its product line[83]. - The company is expanding its molecular product line, including pathogen detection and individual drug molecular testing[83]. Risk Management - The company faces risks from intensified market competition in the in vitro diagnostic industry, which may impact its revenue growth and market share[5]. - The company is exposed to risks related to asset impairment due to potential bad debts from downstream customers and inventory aging[9]. - The company acknowledges the impact of the pandemic on raw material procurement costs and logistics, which may affect its operational performance[10]. - The company has identified key risk factors that may adversely affect its future development strategy and operational goals[130]. Corporate Governance - The company has established a comprehensive corporate governance structure in compliance with relevant laws and regulations, ensuring the safety and stability of its operations[134]. - The company maintains an independent financial department with a complete financial accounting system, ensuring independent financial decision-making[143]. - The company has implemented a performance evaluation and incentive mechanism for senior management, linking compensation to performance[140]. - The company has a clear asset ownership structure, with all intangible and tangible assets owned independently[143]. Shareholder Returns - The company reported a cash dividend of 0.20 yuan per 10 shares (including tax) based on a total of 544,011,487 shares[10]. - The total distributable profit for the year was ¥441,270,603.18, with the cash dividend representing 100% of the total profit distribution[188]. - The company has established a long-term and sustainable shareholder return plan, ensuring that cash dividends are prioritized[186]. Strategic Initiatives - The company plans to enhance its quality management system in line with regulatory changes and improve production efficiency to reduce costs[65]. - The company is actively pursuing opportunities for mergers and acquisitions to enhance its competitive position in the market[152]. - The company aims to leverage academic promotion and brand marketing to enhance product competitiveness and expand brand influence in the market[125]. - The company plans to invest 100 million RMB in new technology development over the next two years[163]. Financial Management - The company reported a significant increase in financing activities, with net cash flow from financing activities growing by 5,125.02 million yuan, a 1190.56% increase year-on-year[59]. - The total cash and cash equivalents increased by 771.30% year-on-year, reaching ¥576,044,140.36, indicating a strong liquidity position[90]. - The company’s asset-liability ratio significantly decreased following the fundraising, providing sufficient financial support for future development[66]. Employee Management - The company has optimized its human resources management, focusing on talent retention and development[7]. - The total number of employees at the end of the reporting period was 522, including 354 at the parent company and 168 at major subsidiaries[178]. - The company has a diverse employee composition with 113 production staff, 159 sales personnel, and 91 technical staff[179].

Financial Performance - The company's revenue for Q3 2021 reached ¥168,789,689.60, representing a 13.54% increase year-over-year[3] - Net profit attributable to shareholders was ¥15,493,626.49, a significant increase of 41.42% compared to the same period last year[3] - The net profit excluding non-recurring items was ¥15,386,596.04, up 42.77% year-over-year[3] - Total operating revenue for the period reached CNY 414,305,890.57, compared to CNY 324,788,378.35 in the previous period, representing an increase of approximately 27.6%[26] - Net profit for the period was CNY 50,012,250.46, significantly higher than CNY 20,588,684.60 in the previous period, reflecting an increase of approximately 142.5%[28] - The net profit attributable to the parent company was CNY 29,057,757.37, compared to CNY 4,997,941.78 in the previous period, marking an increase of about 480.5%[28] - Basic and diluted earnings per share were both CNY 0.067, up from CNY 0.012 in the previous period[28] Assets and Equity - Total assets at the end of the reporting period amounted to ¥2,188,472,231.08, reflecting a 34.37% increase from the previous year[3] - Total assets increased to CNY 2,188,472,231.08 from CNY 1,628,633,453.83, showing a growth of approximately 34.3%[24] - The company's equity attributable to shareholders increased by 45.96% to ¥1,841,531,017.44 compared to the end of the previous year[3] - The company's equity attributable to shareholders rose to CNY 1,841,531,017.44 from CNY 1,261,642,033.09, an increase of approximately 46%[24] Cash Flow - Cash flow from operating activities for the year-to-date decreased by 43.82% to ¥49,300,438.01, primarily due to increased procurement costs[12] - The cash inflow from operating activities for Q3 2021 was CNY 525,904,241.09, an increase from CNY 462,219,476.32 in Q3 2020, representing a growth of approximately 13.8%[31] - The company reported a net cash flow from operating activities of CNY 49,300,438.01, down from CNY 87,760,462.53 in Q3 2020, reflecting a decrease of about 43.7%[31] - The total cash and cash equivalents at the end of Q3 2021 reached CNY 883,052,704.12, up from CNY 344,938,585.52 at the end of Q3 2020, indicating a growth of approximately 156.5%[32] - The total cash outflow for operating activities was CNY 476,603,803.08, an increase from CNY 374,459,013.79 in Q3 2020, representing a rise of about 27.3%[31] Shareholder Information - The total number of common shareholders at the end of the reporting period is 24,723[14] - Guangzhou High-tech Zone Technology Holding Group Co., Ltd. holds 46.07% of shares, totaling 252,133,152 shares[14] - The company completed a private placement of 126,213,152 shares at a price of RMB 4.41 per share, raising a total of RMB 556.6 million[18] - The company's total share capital decreased from 547,265,137 shares to 544,011,487 shares after the cancellation of repurchased shares[18] - The company has a total of 130,064,302 restricted shares at the end of the reporting period[17] Operating Costs and Expenses - The gross profit margin improved, with operating costs increasing by 33.10% year-to-date due to higher sales volume[10] - Operating costs amounted to CNY 350,959,659.12, up from CNY 285,090,782.12, indicating a rise of about 23.1%[27] - Research and development expenses were CNY 24,493,747.55, down from CNY 31,854,532.59, indicating a decrease of about 23.2%[27] Litigation - The company is involved in ongoing litigation with China National Pharmaceutical Group regarding unpaid invoices totaling RMB 35.6 million[19] Fundraising Activities - The company completed a targeted stock issuance, resulting in a 150.84% increase in cash and cash equivalents compared to the beginning of the year[10] - The company reported a 1903.33% increase in net cash flow from financing activities, attributed to the successful fundraising from stock issuance[12] - The company received CNY 553,092,900.32 from financing activities, which included CNY 1,249,500.00 from minority shareholders[32] Inventory and Current Assets - The inventory value as of September 30, 2021, is RMB 102,091,404.75, up from RMB 78,911,957.90 at the end of 2020[22] - The total current assets increased to RMB 1,248,073,282.94 from RMB 688,103,604.97 at the end of 2020[22] Non-recurring Items - The company has no other non-recurring profit and loss items beyond those reported[6] - The company has not utilized the raised funds from the private placement during the reporting period[18] Cash Flow from Investment Activities - The net cash outflow from investing activities was CNY -25,002,514.27, compared to a net inflow of CNY 124,996.34 in the same period last year[32] - The company reported a cash inflow from investment activities of CNY 34,169,202.13, compared to CNY 3,149,805.20 in the same quarter last year[32]

Financial Performance - The company reported a revenue of 300 million RMB for the first half of 2021, representing a year-on-year increase of 15% compared to the same period in 2020[15]. - The net profit attributable to shareholders for the first half of 2021 was 50 million RMB, an increase of 20% year-on-year[15]. - The company's operating revenue for the reporting period was ¥245,516,200.97, representing a year-on-year increase of 39.39% compared to ¥176,133,492.06 in the same period last year[21]. - The net profit attributable to shareholders of the listed company was ¥13,564,130.88, a significant increase of 327.68% from a loss of ¥5,957,646.30 in the previous year[21]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥11,429,604.00, up 431.10% from a loss of ¥3,452,032.39 in the same period last year[21]. - The net cash flow from operating activities was ¥40,908,999.89, an increase of 13.60% compared to ¥36,012,468.08 in the previous year[21]. - The basic earnings per share were ¥0.0325, compared to a loss of ¥0.0143 in the same period last year, reflecting an increase of 327.27%[21]. - The company achieved operating revenue of 245.52 million yuan, a year-on-year increase of 39.39%, and net profit attributable to shareholders of 13.56 million yuan, up 327.68% year-on-year[37]. - The company reported a significant increase in revenue, achieving a total of 1.5 billion RMB for the first half of 2021, representing a year-over-year growth of 20%[125]. - The company reported a significant increase in revenue, achieving a total of 1.2 billion RMB for the first half of 2021, representing a year-over-year growth of 25%[127]. Market Expansion and Strategy - The company plans to expand its market presence by entering three new provinces in China by the end of 2021[15]. - Future guidance indicates a projected revenue growth of 20% for the full year 2021, driven by new product launches and market expansion[15]. - The company is exploring potential mergers and acquisitions to enhance its product portfolio and market reach[15]. - The company is expanding its market presence in Southeast Asia, targeting a 10% market share by the end of 2022[125]. - A strategic acquisition of a local competitor is in progress, which is expected to enhance the company's product portfolio and increase market penetration by 15%[126]. - The company plans to issue shares to specific investors to optimize capital structure and enhance competitiveness[50]. - The company is considering strategic acquisitions to enhance its product portfolio, with a target of completing at least one acquisition by the end of 2021[127]. Research and Development - Research and development expenses increased by 25% in the first half of 2021, totaling 30 million RMB, focusing on new diagnostic technologies[15]. - The company has established a complete and efficient R&D, procurement, production, marketing, and service system for in vitro diagnostic products[32]. - The company has invested 200 million RMB in R&D for new technologies aimed at improving diagnostic accuracy and efficiency[125]. - The company has 48 chemical luminescence reagent projects in various stages of development, with 10 newly initiated projects[45]. - The company is focused on developing products in clinical biochemistry, chemiluminescence, immunoturbidimetry, and molecular diagnostics[61]. - The company emphasizes its investment in R&D, with a team of experts from the in vitro diagnostics and medical device industries, collaborating with renowned universities and research institutions[61]. Product Development and Launches - The company has successfully launched two new diagnostic products in the first half of 2021, contributing to 5% of total revenue[15]. - New product development includes the introduction of three innovative diagnostic products expected to launch by Q4 2021, which are anticipated to contribute an additional 300 million RMB in revenue[126]. - The company is advancing its POCT platform, with 9 related products at various R&D stages[53]. - The company submitted registration applications for 20 new products, including α-L-fucosidase (AFU) assay kits and sdLDL-C measurement kits, with various statuses such as "under review" and "accepted"[58]. Risk Factors - The company faces potential risks related to regulatory changes and market competition, which are detailed in the risk management section of the report[4]. - The company faces risks from industry policy changes, including "sunshine procurement" and "volume-based procurement," which may impact customer structure and sales models[90]. - There is a risk associated with new product development and registration, as failure to obtain medical device registration could slow revenue growth and hinder recovery of R&D investments[92]. - Ongoing COVID-19 pandemic uncertainties may affect the supply chain for raw materials and products, prompting the company to enhance inventory and supply chain management[97]. Corporate Governance and Compliance - The company has established a comprehensive corporate governance structure, with a board of 7 directors, including 3 independent directors, ensuring effective oversight and protection of shareholder rights[110]. - The company actively engages in investor relations, utilizing multiple channels to communicate with investors and protect their legal rights[112]. - The company has committed to strict adherence to its operational and financial commitments, with no breaches reported[137]. - The company has established a commitment to comply with all relevant regulations and company bylaws regarding related party transactions[122]. Environmental and Social Responsibility - The company has invested over 800,000 RMB in new wastewater treatment facilities and an online monitoring system, which are now in normal operation[107]. - The company adheres to various pollution discharge standards, including DB11/307-2013 for wastewater and DB11/139-2015 for boiler emissions, with all emissions meeting regulatory requirements[108]. - The company has not faced any administrative penalties related to environmental issues during the reporting period[109]. - The company has not initiated any targeted poverty alleviation programs during the reporting period and has no plans for such initiatives[118].

Financial Performance - The company's operating revenue for Q1 2021 was ¥115,723,080.99, representing a 107.27% increase compared to ¥55,831,860.18 in the same period last year[7] - The net profit attributable to shareholders was ¥6,269,691.46, a significant turnaround from a loss of ¥15,472,904.88 in the previous year, marking a 140.52% improvement[7] - The net cash flow from operating activities reached ¥15,336,177.92, compared to a negative cash flow of ¥8,407,421.89 in the same period last year, reflecting a 282.41% increase[7] - Basic earnings per share improved to ¥0.0150 from a loss of ¥0.0370, indicating a 140.54% increase[7] - The company reported a net cash flow from operating activities of 15.54 million yuan, a significant increase of 282.41% compared to -8.41 million yuan in the same period last year[21] - Net profit for Q1 2021 was ¥10,683,942.73, a turnaround from a net loss of ¥13,543,999.31 in the same period last year[53] - The company reported a gross profit margin of approximately 8.5% for the current period, compared to a negative margin in the previous year[53] - The financial outlook for the upcoming quarters remains positive, with expectations of continued revenue growth and profitability improvements[53] Assets and Liabilities - The total assets at the end of the reporting period were ¥1,604,638,552.35, a decrease of 1.47% from ¥1,628,633,453.83 at the end of the previous year[7] - The total assets amounted to 1.60 billion yuan, a decrease of 1.47% from the beginning of the year[22] - The company's current assets totaled CNY 663,825,409.45, down from CNY 688,103,604.97 at the end of 2020, indicating a decrease of about 3.5%[43] - Total liabilities decreased to CNY 213,996,392.66 from CNY 249,924,736.88, a decline of about 14.4%[45] - Total liabilities decreased to ¥196,982,044.94 from ¥248,236,588.95 year-over-year, indicating improved financial stability[52] - The company's total equity remained stable at approximately ¥1,430,646,307.08, showing resilience in shareholder value[52] Shareholder Information - The total number of common shareholders at the end of the reporting period was 21,695[10] - The largest shareholder, Guangzhou High-tech Zone Technology Holding Group Co., Ltd., held 125,920,000 shares, accounting for 29.91% of the total shares[10] - The company did not engage in any repurchase transactions among the top 10 shareholders during the reporting period[11] - The total equity attributable to shareholders increased slightly to CNY 1,267,911,724.55 from CNY 1,261,642,033.09, reflecting a growth of approximately 0.5%[46] Research and Development - The company has 60 projects for chemiluminescent reagents and 51 projects for biochemical diagnostic reagents at various development stages[24] - The company has newly registered 2 products for chemiluminescent diagnostic reagents related to infectious disease detection, with 14 products under registration application[24] - Research and development expenses for the quarter were ¥9,259,306.78, slightly down from ¥11,195,543.31 in the previous year, indicating a focus on cost management[52] Market Strategy and Industry Monitoring - The company emphasizes a market strategy of "academic promotion + brand promotion" to enhance overall market outreach and brand recognition[26] - The company is closely monitoring industry policy changes, such as "tiered diagnosis" and "two-invoice system," which may impact product pricing and market dynamics[27] - The company plans to focus on core business and enhance product and technology reserves to improve product structure and quality amid increasing market competition[29] Cash Flow and Investments - The company's cash flow from investing activities was -9.89 million yuan, a decline of 153.68% year-on-year, primarily due to increased cash outflow for fixed asset construction[21] - The net cash flow from financing activities was -38,153,616.67 CNY, a significant decrease from a positive cash flow of 7,457,216.66 CNY in the previous period[62] - The ending cash and cash equivalents balance was 319,826,863.94 CNY, down from 352,531,610.69 CNY at the beginning of the period[62] Miscellaneous - The company reported non-recurring gains and losses totaling ¥499,794.19 for the period[8] - The company reported no non-operating fund occupation by controlling shareholders or related parties during the reporting period[38] - There were no significant changes in net profit forecast for the year, indicating stability in financial performance[36] - The first quarter report was not audited, indicating that the figures may be subject to change upon final review[68]

Financial Performance - The company's revenue for 2020 was approximately ¥471.51 million, a decrease of 8.47% compared to ¥515.14 million in 2019[26]. - The net profit attributable to shareholders for 2020 was approximately -¥50.98 million, representing a decline of 908.09% from a profit of ¥6.31 million in 2019[26]. - The net cash flow from operating activities increased by 8.75% to approximately ¥135.56 million in 2020, compared to ¥124.65 million in 2019[26]. - The total assets at the end of 2020 were approximately ¥1.63 billion, a decrease of 4.99% from ¥1.71 billion at the end of 2019[26]. - The net assets attributable to shareholders decreased by 4.19% to approximately ¥1.26 billion at the end of 2020, down from ¥1.32 billion at the end of 2019[26]. - The basic earnings per share for 2020 was -¥0.12, a decline of 700.00% from ¥0.02 in 2019[26]. - The weighted average return on net assets was -3.95% in 2020, down from 0.48% in 2019[26]. - The company's revenue after deducting non-operating income was approximately ¥449.59 million in 2020, compared to ¥497.90 million in 2019[26]. - The company achieved operating revenue of 471.51 million yuan, a decrease of 8.47% compared to the same period last year, with a net profit attributable to shareholders of -50.98 million yuan, down 908.09% year-on-year[45]. - The company reported a net profit of -50,983,731.69 yuan for the year 2020, indicating a challenging financial performance[146]. Market and Industry Outlook - The company acknowledges the ongoing uncertainty in the global economy and the in vitro diagnostics industry due to the COVID-19 pandemic, which may affect raw material procurement[12]. - The domestic in vitro diagnostic market is expected to continue growing due to factors such as an aging population and increased government investment in healthcare, creating significant demand for the industry[45]. - The in vitro diagnostic industry in China is projected to reach a market size of approximately 700 billion yuan, with significant potential for domestic product substitution, particularly in the chemiluminescence sector[47]. - The in vitro diagnostic market in China exceeded 70 billion yuan in 2019, with a projected growth rate of over 15% in the next five years, significantly outpacing the global growth rate of 6%[129]. - The company aims to enhance its market share in the high-end immunodiagnostics sector, which is currently dominated by foreign giants, by focusing on the development of domestic chemical luminescence products[130]. Research and Development - The company emphasizes the importance of developing new technologies and products to meet increasing market demands, with a focus on accelerating the commercialization of new products[6]. - The company plans to strengthen its research and development management system to mitigate risks associated with new product development and regulatory approvals[6]. - The company reported a significant increase in R&D efforts, focusing on new product development and market expansion strategies[19]. - The company emphasizes R&D investment and has developed a comprehensive innovation system, enhancing product performance and expanding product variety to meet market demands[47]. - The company is focused on enhancing its R&D capabilities, with significant investments aimed at accelerating the commercialization of new products[64]. - The company has established a comprehensive and efficient system for R&D, procurement, production, marketing, and service in the field of in vitro diagnostics[41]. - The company has 46 ongoing projects in the biochemical reagent field, with 27 new projects added in 2020, and 13 biochemical reagent products in the registration process[72]. - The company is actively pursuing regulatory approvals to ensure timely market entry for its new products[96]. - The company is leveraging its research and development capabilities to innovate and expand its offerings in the diagnostics field[97]. Product Development and Offerings - The main products include biochemical diagnostic reagents, immunodiagnostic reagents, coagulation reagents, and various diagnostic instruments, which are widely used in hospitals and medical testing centers[37]. - The company has obtained 57 registrations for chemiluminescence reagent products, covering various disease markers including tumors and cardiovascular diseases[38]. - The company is developing a range of immunoglobulin measurement kits, including IgG and IgM, with registration applications also submitted and under review[96]. - The company is focusing on quantitative measurement of serum components, including lactate dehydrogenase and albumin, with ongoing registration processes[96]. - The company aims to enhance its market presence through the introduction of innovative medical devices and diagnostic products[96]. - The company is committed to advancing its research and development efforts in the field of biochemical testing[96]. - The company is actively developing new products, with several kits in the pipeline, including those for measuring cholesterol and glucose levels[98]. - The company is focusing on expanding its product offerings in the biochemical testing market, which may lead to increased revenue streams in the future[99]. Financial Management and Risks - The company has a high proportion of accounts receivable, which poses a risk due to extended collection periods and potential bad debts from downstream distributors[9]. - The company recognizes the potential for goodwill impairment due to changes in industry policies or competition, which could affect its financial performance[10]. - The company faces risks related to market competition, with an increasing number of domestic and international players in the in vitro diagnostics industry, leading to a potential decline in market share if it does not diversify effectively[5]. - The company reported a significant increase in external purchase costs, which rose by 74.35% to ¥85.66 million, compared to ¥49.13 million in 2019[87]. - The company has established long-term stable partnerships with nearly 500 distributors, achieving sales revenue of 369.02 million yuan through the distribution model and 80.57 million yuan through direct sales, with respective contributions of 82% and 18% to main operating revenue[44]. Governance and Compliance - The company has established a complete corporate governance structure and shareholder rights protection system, ensuring equal treatment of all investors[195]. - The board of directors consists of 7 members, including 3 independent directors, enhancing decision-making fairness and scientificity[196]. - The company guarantees that all related party transactions will be conducted at fair market prices and in accordance with legal requirements, ensuring transparency and compliance[156]. - The company has committed to maintaining its independence in all aspects, including assets, personnel, finance, and operations, in compliance with regulatory requirements[156]. - The company has established a robust governance structure to ensure compliance with laws and regulations, safeguarding shareholder interests[156]. Shareholder Returns and Dividends - The company has not declared any cash dividends or stock bonuses for the year[13]. - The board of directors proposed no profit distribution for 2020, citing the need for funds to support future business expansion and improve long-term profitability[147]. - The company maintains a cash dividend policy that requires at least 20% of the distributable profit to be allocated as cash dividends each year[144]. - The company’s total distributable profit for 2020 was 436,584,958.98 yuan, with no cash dividends declared[148]. - The board's decision to not distribute profits was influenced by the current macroeconomic environment and the company's cash flow situation[147]. Operational Efficiency and Cost Management - The overall financial performance reflects a strategic focus on cost reduction and operational efficiency, positioning the company for future growth[104]. - The company has made changes to the registration of several key medical devices, indicating ongoing compliance and product development efforts[102]. - The company has initiated a stock issuance process to strengthen its capital base, with approval from the China Securities Regulatory Commission received in February 2021[137]. - The company is actively seeking acquisition and collaboration opportunities to expand its product, technology, and industry chain capabilities[138]. Safety and Employee Management - The company reported no safety production accidents or other unusual events in 2020, demonstrating its commitment to employee health and safety[198]. - The company conducted a series of safety awareness activities to improve employee safety consciousness and self-protection awareness during the pandemic[199]. - Employee safety education included onboarding safety training for new employees and emergency drills for chemical leaks and fire evacuations[199]. - The company implemented regular safety inspections and communicated with responsible parties to address identified hazards, with a focus on major holidays and pandemic prevention[200].